介素-6和肺高血压:从病理学到治疗
Wei-Jie Xu1, Qiong Wu2, Wen-Ni He3
1Department of Clinical Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Frontiers in immunology
|July 14, 2023
概括
洲际蛋白-6 (IL-6) 涉及到肺高血压 (PH) 病变的发生. 针对IL-6炎症通路为PH患者提供了潜在的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部医学 肺部医学
- 血管生物学 血管生物学
背景情况:
- 肺高血压 (PH) 是一种严重的血管疾病,具有复杂,不清楚的发病因子.
- 炎症因素越来越被认为是PH发展的关键因素.
- 参与免疫调节的细胞因子 - - 介质素-6 (IL-6) 在PH患者中升高,并与肺功能减弱有关.
研究的目的:
- 审查IL-6在肺高血压进展中的作用.
- 阐明通过IL-6影响PH的特定机制和信号通路.
- 总结目前针对IL-6和相关炎症途径的治疗策略,以治疗PH.
主要方法:
- 对研究研究IL-6在肺高血压的文献综述.
- 分析涉及IL-6在PH病变发生过程中的信号通路和分子机制.
- 针对PH的炎症途径的现有药理干预措施的摘要.
主要成果:
- 在PH患者的血清中IL-6水平升高,与肺功能负相关.
- IL-6在调解炎症和加速PH过程中发挥着重要作用.
- 已经确定了涉及IL-6的各种信号通路在PH发育中至关重要.
结论:
- IL-6是肺高血压炎症发病的关键媒介.
- 准IL-6及其相关信号通路代表了PH的有前途的治疗途径.
- 本综述为开发针对PH的向治疗提供了理论基础.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
230
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
230
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.9K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
268
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
268
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
209
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209


